The biopharmaceutical industry has spent decades treating quality as a necessary evil. That mindset is costing us more than we know - and the companies that figure this out first, are winning.
Ask anyone who has led a quality organization through a budget cycle, and the story sounds familiar: quality sits on the ledger as overhead. A regulated necessity. A cost of doing business. The quality team is asked to justify its headcount, defend its spend, and find efficiencies - often in the same breath as it is being held responsible for keeping a Warning Letter off the front page of the FDA's website.
This framing is not just wrong. It is costly.
The numbers tell a different story - and in July 2025, a regulatory agency itself made the case. FDA's Center for Drug Evaluation and Research (CDER) Office of Pharmaceutical Quality published a 21-page white paper, Quality Management Initiatives in the Pharmaceutical Industry: An Economic Perspective, which sets out in plain economic terms why quality management is no longer just a compliance obligation but a measurable profit lever and public health safeguard. The paper documents that roughly two thirds of medicine supply chain challenges begin as a quality issue, and it presents real-world case studies showing that companies investing in mature quality systems achieve significant reductions in defects, waste, and operational costs - with even incremental investments delivering positive returns. FDA's own conclusion: strategic investments in quality management have the potential to yield returns for both companies and for public health. That is the regulator telling industry that quality pays.
The flip side is just as stark: the costs of not investing in quality dwarf the cost of doing quality well. And yet the budget conversation rarely starts there.
It is time to reframe the question. Not "What does quality cost?" but "What is quality worth?"
The Cost-Center Mindset and Where It Leads
The cost-center framing of quality did not emerge from nowhere. Regulatory compliance is indeed expensive. Quality Management Systems require infrastructure, expertise, and time. And in an industry under relentless pressure to compress development timelines and cut costs of goods sold, quality can look like the one function that produces no revenue and slows everything down.
But follow that logic far enough and you arrive somewhere deeply familiar to anyone in this industry: the 483 observation, the Warning Letter, the consent decree, the product recall. You arrive at companies that became cautionary tales - names we all know. You arrive at batch failure rates that consume margins, inventory write-offs that destabilize supply chains, and Complete Response Letters that delay launches by years. And when the 483 does arrive, it rarely tells the whole story - it surfaces what investigators happened to see, in the areas they visited, during the time they were on site. What it signals about the rest of the operation is often the more important question.
The cost-center mindset, pursued aggressively enough, does not save money. It defers costs - and multiplies them.
What we rarely calculate is the full economic burden of poor quality. It includes not only the visible costs - failed batches, rework, investigations, regulatory responses - but also the invisible ones: the first-in-class asset that lost its market window because a manufacturing failure pushed the launch eighteen months to the right, the partnership that was not renewed because a CDMO's inspection track record was unreliable, the licensing deal that collapsed during due diligence when a potential partner looked at the site's deviation trends. The pattern is consistent: the costs of poor quality that never show up on a quality report are often the ones that matter most to the business.
Those costs never appear on the quality department's budget. But they represent real opportunity cost - and they belong in every conversation about the value of quality investment.
What Quality Excellence Actually Enables
When quality has a seat at the leadership table and is designed into the operation - rather than after the fact - it becomes a performance multiplier. The benefits are not hypothetical. They are measurable, and they accrue directly to business performance.
Faster time to market. A robust quality system means a manufacturing process that works the way it is supposed to work, consistently, every time. That translates to higher batch success rates, shorter disposition times, and the ability to enter a Pre-Approval Inspection with confidence rather than anxiety. In a competitive market, being six months faster to launch than a competitor is not a quality outcome. It is a revenue outcome, and one that cannot be recovered if missed.
Lower total cost of goods. Right-first-time manufacturing is cheaper manufacturing. When batches succeed, when deviations are rare, when CAPA systems actually close the root cause rather than document the activity, the cost of goods sold goes down. Not because quality was cut - because quality was built in. Process design and validation, done well up front, eliminates the rework cycles and batch failures that inflate production costs.
Better partnerships and stronger supply chains. Sponsors evaluating CDMOs look at inspection history. Licensing partners conducting due diligence look at quality system maturity. Private equity firms look at operational risk. A quality organization that functions as a strategic asset - one that is transparent, predictive, and capable - is a differentiator in every one of those conversations. In fact, an acquisition that looks clean on paper can close with a manufacturing operation riddled with data integrity gaps. Quality system maturity, assessed rigorously before the deal closes, is where real enterprise value is protected.
Regulatory confidence and market access. A site with a strong quality culture and a track record of clean inspections maintains market access. It does not lose months to remediation. It does not lose commercial product while manufacturing is suspended. It does not have to rebuild trust with regulators from a position of enforcement. The ability to manufacture and supply without interruption is itself a competitive advantage.
The Deming Lesson Worth Revisiting
W. Edwards Deming taught Japanese manufacturers in the postwar decades that quality and efficiency were not in tension - they were the same thing. Companies that pursued quality relentlessly did not just make better products. They made them faster, with less waste, at lower cost. Toyota did not become globally dominant in spite of its quality culture. It became dominant because of it - and the rest of Japan's manufacturing sector followed.
The lesson was not lost on manufacturing industries broadly. It is a lesson the biopharma industry is still putting into practice.
The opportunity is to move quality functions from primarily retrospective to genuinely proactive - from catching errors after they happen to preventing them by design. Too often, quality systems are oriented toward documenting investigations, writing CAPAs, and tracking closure. These activities are necessary. They are not sufficient. And when they consume the majority of the quality organization's bandwidth, something important goes wrong: quality becomes a reviewer of outcomes rather than a shaper of processes.
The most effective quality functions are not primarily reactive. They are embedded in process design. They are present at the bench, in the tech transfer, in the manufacturing suite. They build quality into the process so that the rearview-mirror activities - the deviations, the investigations, the batch record reviews - reflect a system that is learning and improving, rather than one that is perpetually firefighting.
This is not just an organizational design principle. It is a learning principle. Scientific evidence demonstrates that deep, meaningful capability is built experientially - through doing, not just through reading or being told. Organizations that build quality culture by embedding learning into the work itself, rather than separating training from execution, develop competency that is resilient, retained, and transferable. The distinction matters enormously on the manufacturing floor, where the gap between knowing a procedure and executing it under real conditions can be the difference between a clean batch and a deviation.
That shift is not a compliance strategy. It is a business strategy.
The Regulatory Landscape Makes This More Urgent, Not Less
For anyone still clinging to the notion that reduced regulatory scrutiny creates breathing room on quality investment, the data says otherwise - and it says so emphatically.
FDA drug quality inspections increased 27% from FY2023 to FY2024, with foreign inspections reaching an all-time high at 62% of all quality assurance inspections. FY2025 added nearly 700 more inspections on top of that. Warning letters are up. Untitled letters - formal notices of violation that were nearly nonexistent in prior years - surged from 4 in FY2023 and 5 in FY2024, to 58 in FY2025. The agency has expanded unannounced inspections at foreign manufacturing facilities, specifically targeting sites in China and India that supply a significant share of the U.S. market's active pharmaceutical ingredients. The direction of travel is unambiguous: scrutiny is increasing, not decreasing.
And then there is Elsa.
In June 2025, FDA launched an internal AI system designed to bring analytical precision to how the agency tracks manufacturer commitments. When a company responds to a Form 483 observation or a Warning Letter with a corrective action commitment, Elsa tracks it. The era of submitting a CAPA response and hoping it fades from institutional memory is over. Regulators now have the tools to know exactly what you promised, when you promised it, and whether you delivered.
This changes the calculus fundamentally. It is no longer sufficient to make the right commitments on paper. Organizations must have the quality infrastructure to execute on those commitments - reliably, on schedule, and in a way that holds up under follow-up scrutiny. That requires exactly the kind of mature, embedded quality function this article argues for. Not a reactive compliance team scrambling to respond to findings, but a proactive quality organization that doesn't generate the kind of findings that require commitments in the first place.
The risks of poor quality do not wait for an inspection regardless. Batch failures happen whether or not an investigator is on site. Drug shortages - a matter of increasing public and political urgency - trace directly to quality failures in manufacturing. The consequences to patients, to business continuity, and to company reputation are not gated by regulatory enforcement. But the regulatory environment has removed any remaining argument for complacency.
It is also worth remembering what an inspection is - and what it is not. An inspection is a snapshot. Investigators see what they see during the time they are on site, in the areas they visit, reviewing the records they request. What they find, however, is rarely isolated. A data integrity observation in one department is seldom a one-room problem. A deviation trending in one manufacturing suite often signals a systemic condition that exists elsewhere in the operation - in areas the inspector never entered, on documents never pulled. Experienced quality leaders understand that a Form 483 is not just a list of findings. It is a diagnostic signal about the health of the broader system.
The question is no longer whether FDA will find quality gaps. It is whether your organization understands what those findings are telling you about the gaps they didn't find - and whether you will have closed them first.
Making the Business Case Inside Your Organization
For quality professionals making this case internally, the framing matters enormously.
Lead with the numbers that leadership already cares about. Not compliance rates - those matter, but they do not move the boardroom. Instead, calculate the cost of poor quality as a line item: batch failure rates multiplied by batch value, inventory write-offs, regulatory response costs, remediation labor, and the revenue opportunity cost of delayed launches. Make the hidden visible. FDA's own 2025 white paper - which documents that roughly two thirds of medicine supply chain challenges begin as a quality issue - is exactly the kind of authoritative, external reference that reframes the conversation from "what does quality cost" to "what is poor quality costing us already."
Then make the case for what investment buys. Not simply more audits or more documentation - but the upstream capabilities that reduce downstream costs. Robust process design and validation. Workforce training that builds genuine competency, not just training records. Quality system infrastructure that is predictive rather than reactive. The argument is not that quality should cost more. It is that the right quality investment costs less, in total, than the quality failures it prevents - and the significant opportunity value it provides by accelerating time to market.
The regulatory environment now adds a layer to this argument that did not exist before. With FDA's Elsa system tracking every corrective action commitment a company makes, the cost of an inadequate quality infrastructure is no longer just operational - it is a reputational liability and a documented, traceable regulatory risk, at least in the U.S. market where Elsa now captures and tracks every commitment made to the agency. Leadership needs to understand that a CAPA commitment is now a tracked obligation. The organization must be able to execute, not just respond. That is a business risk conversation, not a compliance conversation, and it belongs in the boardroom.
Finally, connect quality performance to the business decisions that leadership is already making. When the company is evaluating a CDMO, quality should be at the table. When a licensing deal is in due diligence, quality data should be part of the asset package. When investor presentations are being prepared, manufacturing reliability and quality track record belong in the story. Quality is not a support function for these conversations. It is one of the primary inputs.
The Mindset Shift That Changes Everything
There is a version of quality that is fundamentally defensive. It exists to prevent bad outcomes, satisfy regulators, and avoid disasters. In this version, quality has succeeded when nothing goes wrong.
There is another version of quality that is fundamentally generative. It exists to build the operational capability that makes good outcomes consistently achievable. In this version, quality has succeeded when the organization can bring new therapies to patients faster, at lower cost, with less disruption, and with the kind of reliability that earns trust from partners, regulators, and the market.
The first version is a cost center. The second is a competitive advantage.
The biopharmaceutical industry's patients deserve the second version. And increasingly, the economics demand it.
How QxP Can Help
At QxP, we have spent more than a decade helping biopharmaceutical companies make exactly this transition - from quality as a compliance burden to quality as an engine of business performance.
Our approach is built around sustainability, not just remediation. We don't parachute in, produce a report, and leave. At the core of everything QxP does is our Teach & Do methodology - the principle that sustainable improvement occurs when organizations execute and learn simultaneously. Rather than simply delivering solutions, our senior experts work alongside your teams, transferring capability in real time so that the knowledge, judgment, and quality culture built during an engagement remain embedded in your organization long after it ends. In 12 out of 12 recent partnerships, our clients achieved their business goals and sustained compliance long after our engagement ended - with both strategic quality management and quality systems that kept pace with their growth rather than simply holding the line. That is the standard we hold ourselves to.
Specifically, QxP helps organizations that are ready to treat quality as a strategic asset by:
- Conducting enterprise quality and compliance risk assessments that translate quality system gaps into business risk language your leadership can act on
- Building and maturing Quality Management Systems designed not just to satisfy regulators, but to drive operational performance - reduced batch failures, faster disposition, lower COGM
- Preparing sites for Pre-Approval Inspections and routine regulatory scrutiny, not as a sprint before an inspection, but as a durable organizational capability
- Supporting technical due diligence for acquisitions, licensing transactions, and CDMO selection - ensuring that quality system maturity is properly weighed in investment and partnership decisions
- Developing workforce capability through Virtuosi®, our IACET-accredited immersive training platform, so that quality culture is built at the operator level, not just documented in SOPs
Whether you are a sponsor preparing for your first commercial launch, a CDMO competing for business in an increasingly selective market, or an investor evaluating manufacturing risk in a life sciences transaction, the conversation about quality as competitive advantage starts the same way: with an honest assessment of where you are today and what it would mean - operationally and financially - to get to where you need to be.
If you're ready to have that conversation, let's talk.
Elizabeth Thomae is VP, Business Development at Quality Executive Partners. She works with biopharmaceutical companies, CDMOs, and life sciences investors to align quality and operational strategy with business objectives - including technical due diligence, CDMO evaluation, and commercial readiness. Prior to QxP, Elizabeth held strategic leadership, business development and commercial roles across the life sciences industry.
